MedTrace Logo

The Efficacy & Safety of the UAS Immunotherapy Protocol

NCT01699659 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2012-10-04

No results posted yet for this study

Summary

Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.

Conditions

  • Perennial Allergic Rhinitis With Seasonal Variation

Interventions

OTHER

allergen immunotherapy

allergy shots

Sponsors & Collaborators

  • United Allergy Services

    lead INDUSTRY

Principal Investigators

  • Frederick M Schaffer, M.D. · United Allergy Services

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699659 on ClinicalTrials.gov